Can genetics predict risk for alcohol dependence?

Inherited variations affect response to alcohol and to alcoholism treatments

Children of alcoholics have a 40% to 60% increased risk of developing severe alcohol-related problems—a harsh legacy recognized for >30 years. Now, as the result of rapidly growing evidence, we can explain in greater detail why alcoholism runs in families when discussing alcohol dependence with patients.

Individuals vary in response to medications and substances of abuse, and genetic research is revealing the heritable origins. Numerous genetic variations are known to influence response to alcohol, as well as alcoholism’s pathophysiology, clinical manifestations, and treatment. Pieces are still missing from this complex picture, but investigators are identifying possible risk factors for alcoholism and matching potential responders with treatments such as naltrexone and acamprosate.

This article provides a progress report on contemporary genetic research of alcoholism. Our goal is to inform your clinical practice by describing:

- new understandings of the genetics of alcoholism
- how researchers identify relationships between genetic variations and clinical/behavioral phenomena
- practical implications of this knowledge.

Genetic variations and risk of addiction

No single gene appears to cause alcoholism. Many genetic variations that accumulated during evolution likely contribute to individual differences in response
to alcohol and susceptibility to developing alcohol-related problems. A growing number of genetic variations have been associated with increased alcohol tolerance, consumption, and other related phenotypes.

Like other addictive substances, alcohol triggers pharmacodynamic effects by interacting with a variety of molecular targets (Figure 1). These target proteins in turn interact with specific signaling proteins and trigger responses in complex functional pathways. Genetic variations may affect the structure of genes coding for proteins that constitute pathways involved in alcohol’s effects on target proteins (pharmacodynamics) or its metabolism (pharmacokinetics). If such variations alter the production, function, or stability of these proteins, the pathway’s function also may be altered and produce behavioral phenotypes—such as high or low sensitivity to alcohol’s effects.
Alcoholism-related phenotypes. DSM-IV-TR diagnostic criteria include some but not all of the multiple phenotypes within alcoholism’s clinical presentation. Researchers in the Collaborative Studies on Genetics of Alcoholism (COGA) identified chromosome regions linked to alcoholism-related phenotypes, including:

- alcohol dependence
- later age of drinking onset and increased harm avoidance
- alcoholism and depression
- alcohol sensitivity
- alcohol consumption

To identify genes of interest within these chromosome regions, researchers used transitional phenotypes (endophenotypes) that “lie on the pathway between genes and disease,” and allowed them to characterize the neural systems affected by gene risk variants. As a result, they found associations among variations in the GABRA2 gene, (encoding the alpha-2 subunit of the GABAA receptor), specific brain oscillations (electrophysiologic endophenotype), and predisposition to alcohol dependence. By this same strategy, researchers discovered an association between the endophenotype (low-level of response to alcohol) and some genotypes, including at least 1 short allele of the serotonin transporter gene SLC6A4.

Alcohol metabolism

Alcohol is metabolized to acetic acid through primary and auxiliary pathways involving alcohol and acetaldehyde dehydrogenases (ADH/ALDH) and the microsomal ethanol oxidizing system (cytochrome P-450 [CYP] 2E1) (Figure 2). Auxiliary pathways become involved when the primary pathway is overwhelmed by the amount of alcohol needed to be metabolized. Catalase and fatty acid ethyl ester synthases play a minor role under normal conditions but may be implicated in alcohol-induced organ damage.

ADH/ALDH pathway. From one individual to another, the ability to metabolize ethyl alcohol varies up to 3- to 4-fold. In European and Amerindian samples, a genetic link has been identified between alcoholism and the 4q21-23 region on chromosome 4. This region contains a cluster of 7 genes encoding for alcohol dehydrogenases (ADH), including 3 Class I genes—ADH1A, ADH1B, and ADH1C—coding for the corresponding proteins that play a major role in alcohol metabolism.
samples, alleles encoding high activity enzymes (ADH1B*47His and ADH1C*349Ile) are significantly less frequent in alcoholics than in nonalcoholics.

Mitochondrial ALDH2 protein plays the central role in acetaldehyde metabolism and is highly expressed in the liver, stomach, and other tissues—including the brain. The ALDH2*2 gene variant encodes for a catalytically inactive enzyme, thus inhibiting acetaldehyde metabolism and causing a facial flushing reaction. The ALDH2*2 allele has a relatively high frequency in Asians but also is found in other populations. Meta-analyses of published data indicate that possessing either of the variant alleles in the ADH1B and ALDH2 genes is protective against alcohol dependence in Asians.

The ADH4 enzyme catalyzes oxidation or reduction of numerous substrates—including long-chain aliphatic alcohols and aromatic aldehydes—and becomes involved in alcohol metabolism at moderate to high concentrations. The -75A allele of the ADH4 gene has promoter activity more than twice that of the -75C allele and significantly affects its expression.

Genetic variations affect the efficiency of primary and auxiliary pathways by which ethyl alcohol is metabolized to acetaldehyde and acetic acid. Auxiliary pathways become involved when the primary pathway is overwhelmed by the amount of alcohol to be metabolized. ADH: alcohol dehydrogenase; ALDH: acetaldehyde dehydrogenase; P450: cytochrome P450, family 2, subfamily E, polypeptide 1; A/G SNP: adenine/guanine single nucleotide polymorphism.

Clinical Point

From one individual to another, the ability to metabolize ethyl alcohol varies up to 3- to 4-fold.
polymorphism (SNP)—at exon 9, has been associated with an increased risk for alcohol and drug dependence in European Americans.\(^{26}\)

Finally, variations in the ADH7 gene may play a protective role against alcoholism through epistatic effects.\(^{27}\)

The CYP 2E1 pathway has low initial catalytic efficiency compared with the ADH/ALDH pathway, but it may metabolize alcohol up to 10 times faster after chronic alcohol consumption or cigarette smoking and accounts for metabolic tolerance.\(^{26}\) CYP 2E1 is involved in metabolizing both alcohol and acetaldehyde.\(^{29}\) The CYP 2E1*1D polymorphism has been associated with greater inducibility as well as alcohol and nicotine dependence.\(^{30}\)

Thus, linkage and association studies support the association of phenotypes related to alcohol response and dependence with variations in genes that code for proteins involved in alcohol’s pharmacodynamic and pharmacokinetic effects. Each of these findings is important, but conceptual models organizing them all and explaining their role in alcohol’s effects and predisposition to alcoholism have yet to be constructed.

### Phenotype-genotype relationships

Alcohol—unlike most other addictive substances—does not have a specific receptor and is believed to act by disturbing the balance between excitatory and inhibitory neurotransmission in the neural system. Consequently, researchers explore relationships between genetics and alcohol-related problems using 2 approaches:

- **Forward genetics** (discovering disease-related genes via genome-wide studies and then studying their function; examples include linkage and genome-wide association studies [GWAS]).
- **Reverse genetics** (testing whether candidate genes and polymorphisms identified in animal studies as relevant for biological effects also exist in humans and are relevant to the phenotype).\(^{31}\)

When searching for relationships between genotypes and phenotypes, both approaches must take into account a framework of functional anatomic and physiologic connections (**Figure 3**).

### Linkage studies

The goal of linkage studies is to find a link between a phenotypic variation (ideally a measurable trait, such as number of drinks necessary for intoxication) and genotype. This can be achieved through linkage analysis, which involves comparing genetic markers across families to identify regions of the genome that are inherited together, suggesting a genetic predisposition to the trait.

### Clinical Point

CYP 2E1 may metabolize alcohol up to 10 times faster after chronic alcohol consumption or cigarette smoking.

---

**Figure 3**

2 ways to seek relationships between genes and behavior

<table>
<thead>
<tr>
<th>Behavior (phenotypes)</th>
<th>Relapse, craving, tolerance/side effects, etc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intermediate phenotypes (endophenotypes)</td>
<td>Biological markers; pharmacokinetic and pharmacodynamic, EEG, etc.</td>
</tr>
<tr>
<td>Brain function (circuits)</td>
<td>Neurochemistry (glutamate, 5-HT, DA) vs function (frontal cortex/control), nucleus accumbens/reward, amygdala/anxiety, etc.)</td>
</tr>
<tr>
<td>Cellular function (pathways)</td>
<td>Signaling, metabolism, LTP/LTD, etc.</td>
</tr>
<tr>
<td>Gene expression</td>
<td>RNA transcription, translation, protein folding, sorting, degradation, etc.</td>
</tr>
<tr>
<td>Gene variations (genotypes)</td>
<td>SNPs, VNTRs, duplications, insertions, deletions, etc.</td>
</tr>
</tbody>
</table>

Researchers use ‘forward’ and ‘reverse’ genetics to connect behavioral phenotypes with predisposing genotypes. Each approach must consider intermediary functional anatomic and physiologic levels (black box), as shown in this conceptual framework.

DA: dopamine; EEG: electroencephalography; 5-HT: serotonin; LTD: long-term depression; LTP: long-term potentiation; RNA: ribonucleic acid; SNPs: single nucleotide polymorphisms; VNTRs: variable number tandem (triplet) repeats
and the chromosomal marker expected to be in the vicinity of the disease-specific gene variation. An advantage of linkage studies is that they can be started without knowing specific DNA sequences. Their limitations include:

- limited power when applied to complex diseases such as alcoholism
- they do not yield gene-specific information
- their success is highly dependent on family members’ willingness to participate.

**Association studies.** Candidate gene-based association studies are designed to directly test a potential association between the phenotype of interest and a known genomic sequence variation. This approach provides adequate power to study variations with modest effects and allows use of DNA from unrelated individuals. The candidate gene approach has revealed associations between specific genomic variations and phenotypes related to alcohol misuse and alcoholism (Table).

Like linkage studies, association studies...
have their own challenges and limitations, such as:

- historically high false-positive rates
- confounding risks (allele frequencies may vary because of ethnic stratification rather than disease predisposition).

To address these challenges, researchers must carefully choose behavioral, physiologic, or intermediate phenotypes and genotype variations, as well as control subjects and sample sizes. Replication studies are necessary to rule out false-positive associations. In fact, only some of the findings depicted in the Table (page 69)—those related to GABRA2 and GABRA6 and few other genes—have been replicated.

**Genome-wide association studies** are a powerful new method for studying relationships between genomic variability and behavior. With GWAS, thousands of DNA samples can be scanned for thousands of SNPs throughout the human genome, with the goal of identifying variations that modestly increase the risk of developing common diseases.

Unlike the candidate gene approach—which focuses on preselected genomic variations—GWAS scans the whole genome and may identify unexpected susceptibility factors. Unlike the family-based linkage approach, GWAS is not limited to specific families and can address all recombination events in a population.

Challenges are associated with GWAS, however, and include:

- need for substantial numbers (2,000 to 5,000) of rigorously described cases and matched controls
- need for accurate, high-throughput genotyping technologies and sophisticated algorithms for analyzing data
- risk of high false-positive rates related to multiple testing
- inability to scan 100% of the genome, which may lead to false-negative findings.

**Clinical implications**

Genomic research is increasing our understanding of alcohol’s pharmacokinetic and pharmacodynamic interactions and of potential genetic associations with alcoholic phenotypes. These insights may lead to discovery of new therapies to compensate for specific physiologic and behavioral dysfunctions. For example, medications with pharmacologic profiles complimentary to addiction-related physiologic/behavioral deficits might be designed in the future.

Likewise, new understandings about genetic variability may allow us to predict an individual’s ability to tolerate and respond to existing medications used to treat alcohol dependence. For example, in studies of alcoholic and nonalcoholic subjects:

- Individuals with the 118G variant allele of the μ-opioid receptor may experience a stronger subjective response to alcohol and respond more robustly to naltrexone treatment than do carriers of the more common 118A allele.32

- Persons with a functional variation in the DRD4 gene (7 repeat allele—DRD4L) coding for type 4 dopamine receptor reported greater euphoria and reward while drinking alcohol and reduced alcohol consumption during 12-week treatment with olanzapine, a DRD2/DRD4 blocker.33

Applying this approach to the study of acamprosate has been difficult because of uncertainty about which protein molecules it targets. Variation in the Per2 gene (coding for protein involved in the circadian cycle) continued on page 73

**Bottom Line**

Genomic research is in the process of identifying genetic variations that predispose to alcohol dependence. Investigations are underway that may allow clinicians to match potential responders with alcoholism treatment options, based on patients’ genetic profiles.
has been shown to be associated with brain glutamate levels, alcohol consumption, and the effects of acamprosate, although these interactions require further investigation. Pharmacogenomics of alcoholism treatment is in a very early stage of development. Findings require replication in different clinical samples and functional analysis. At the same time, if the reported association between the μ-opioid receptor genetic variation and naltrexone’s treatment efficacy is confirmed, this finding could help to guide clinical practice. Studies of genomic predictors of other medications’ efficacy and tolerability for alcoholism treatment would be expected to follow.

References